| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 9, 2021, approved the fiscal year 2022 third quarter cash dividend of $0.63 per ordinary share, representing a 9 percent...
Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021. Key Highlights Revenue of $7.8 billion increased 3% reported...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam™ Small Bowel 3...
Four external appointments include new digital innovation leader, head of global strategy and two Operating Unit President roles within the Neuroscience Portfolio DUBLIN, Nov. 15, 2021...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its inclusion in the Dow Jones® Sustainability World Index (DJSI World) as one of the world's leading companies...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2022 on Tuesday, November 23, 2021....
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its ambition to achieve net zero carbon emissions by fiscal year (FY) 2045 across its operations and value chain...
Transfemoral access added into landmark APOLLO Pivotal Trial following IDE approval from FDA DUBLIN and ORLANDO, Fla., Nov. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ -- Medtronic plc...
New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO,...